Cell Therapy Deals Are Up 800% in 2026 — Here's the Data

Eight cell therapy deals closed between March and September 2026, up from zero in the prior six-month window — an 800% surge that marks the sharpest modality-specific acceleration in biopharma partnering this year. The comparison periods (September 2025–March 2026 vs. March 2026–September 2026) tell a stark story: Big Pharma went from sitting on the sidelines to deploying over $30 billion in total deal value across cell therapy licensing agreements in a single half-year sprint. This isn't a gradual thaw — it's a coordinated land grab by companies that concluded their internal pipelines can't keep pace with the clinical and manufacturing breakthroughs happening at mid-cap biotechs.

The Data — Cell Therapy Deal Activity, Period over Period

The zero-to-eight jump is dramatic, but the raw deal count understates the magnitude. When you layer in total deal values — $11.3B (Bio-Techne/Merck KGaA), $7B (Kelonia/Lilly), $1.5B (Poseida/Roche) — the capital deployed per deal is exceptionally high. This isn't early-stage option buying. These are full-commitment partnerships with significant near-term financial exposure for the licensees. Check the latest figures against historical norms on our Deal Benchmarks page — cell therapy TDVs in 2026 are running 2–3x the modality median from 2023–2024.

What's Driving the Trend

Three forces converged simultaneously. First, manufacturing maturity finally crossed the credibility threshold. The perennial knock on cell therapy — that autologous and even allogeneic approaches couldn't scale — lost its teeth as companies like MaxCyte, Poseida, and Kelonia demonstrated next-generation delivery and manufacturing platforms (non-viral gene insertion, in vivo programming, scalable allogeneic architectures) that derisk commercial viability. Pharma BD teams that spent 2024–2025 in diligence mode saw enough process data to move.

Second, competitive pressure forced the timeline. Lilly's $7B Kelonia deal and Merck KGaA's $11.3B Bio-Techne deal didn't happen in isolation — they happened within five weeks of each other. When one top-10 pharma moves on a platform-level cell therapy asset, rivals accelerate. Pipeline gaps in oncology and autoimmune disease — particularly in solid tumors and lupus — created urgency. Companies that waited risked being locked out of differentiated platforms entirely.

Third, the FDA's regulatory posture shifted from cautious to constructive. Accelerated approval pathways for cell therapies broadened in late 2025 and early 2026, with CBER signaling willingness to accept novel manufacturing endpoints. This reduced the perceived regulatory risk premium that had historically suppressed deal valuations. BD teams recalculated risk-adjusted NPVs upward, and boards approved larger commitments.

Notable Deals

Bio-Techne / Merck KGaA ($11.3B TDV) is the headline deal and one of the largest cell therapy licensing agreements ever structured. The two related filings in June suggest a staged commitment — potentially an initial agreement expanded within two weeks as diligence on additional programs completed. This is a platform-level acquisition of capability, not a single-asset license. Merck KGaA is buying manufacturing infrastructure as much as pipeline.

Kelonia / Lilly ($7B TDV) signals Lilly's bet on in vivo cell programming — engineering cells inside the patient's body rather than extracting, modifying, and reinfusing them. At $7B in total deal value, Lilly is pricing in the possibility that Kelonia's lentiviral platform becomes the backbone of its next-generation oncology and immunology franchises. This is a conviction bet, and it's priced accordingly.

Poseida / Roche ($1.5B TDV) is the most traditional of the group — an allogeneic CAR-T play with clinical-stage assets. Roche paid less in headline value but arguably got a more de-risked package. For BD professionals, the contrast is instructive: platform deals command 3–5x the TDV of single-program licenses in the current market.

The MaxCyte / Genentech deal rounds out the picture. MaxCyte's electroporation technology underpins dozens of cell therapy programs industry-wide. Genentech's licensing of this enabling technology — rather than building in-house — confirms that even the most capable pharma R&D organizations are choosing speed over internal control.

What This Means for BD Teams Right Now

If you're a biotech with a differentiated cell therapy platform, this is an unambiguous seller's market. Five deals with disclosed TDVs exceeding $1B apiece in a single quarter is exceptional by any historical standard. Scarcity of late-stage and platform-level assets is compressing timelines and expanding economics. If you have clinical data and a scalable manufacturing story, you should be running a competitive process — not entertaining single-party exclusivity.

For buyers, the calculus is more complex. Waiting is expensive: every month another platform gets locked up. But the TDV inflation is real. Deals that would have closed at $2–3B total value in 2024 are now clearing at $7–11B. BD teams should pressure-test their valuation models against current comps — use our Solidus calculator to benchmark upfront-to-TDV ratios and milestone structures against the latest disclosed transactions.

Deal structures are evolving in response to the seller's market. We're seeing fewer option-based structures and more outright co-development agreements with shared economics. Milestone-heavy backends are giving way to larger upfronts and equity stakes. Licensors with leverage are demanding co-promote rights in key markets and retaining ex-US rights where possible. If your term sheet still looks like 2023, expect pushback.

One structural trend worth watching: platform deals are overtaking single-indication licenses as the dominant transaction type. Pharma companies are paying premium prices to lock up manufacturing know-how and delivery technology across multiple programs rather than licensing a single clinical-stage asset. BD teams evaluating cell therapy opportunities should frame their pitch around platform breadth, not just lead program data.

Benchmark your deal against current market rates. Cell therapy licensing economics have shifted dramatically in 2026. Use the Ambrosia calculator to model your transaction against real comparable deal data and ensure you're negotiating from an informed position.